Pfizer’s TALZENNA and XTANDI cut prostate cancer progression risk by 52%, but who benefits most?
Pfizer wins FDA approval for TALZENNA plus XTANDI in earlier metastatic prostate cancer. See how a 52% progression-risk reduction changes treatment.
Pharma & Biotech